Risk mitigation for opioid overdose

Risk mitigation for opioid overdose is a clinical harm reduction strategy rather than an isolated disease, aimed at preventing life-threatening opioid toxicity in populations prescribed high-dose opioid therapy, individuals with opioid use disorder, or those at risk of illicit opioid exposure

Risk mitigation for opioid overdose is a clinical harm reduction strategy rather than an isolated disease, aimed at preventing life-threatening opioid toxicity in populations prescribed high-dose opioid therapy, individuals with opioid use disorder, or those at risk of illicit opioid exposure

Risk mitigation for opioid overdose is a clinical harm reduction strategy rather than an isolated disease, aimed at preventing life-threatening opioid toxicity in populations prescribed high-dose opioid therapy, individuals with opioid use disorder, or those at risk of illicit opioid exposure Clinical risk mitigation centers on identifying individuals with elevated vulnerability—such as those receiving high daily morphine milligram equivalents, taking concurrent central nervous system depressant...

Opioid overdose primarily impacts the central nervous and respiratory systems through profound mu-opioid receptor agonism in the brainstem, which blunts hypercapnic and hypoxic ventilatory drive Pathophysiologically, this progressive central nervous system and respiratory depression can result in profound bradypnea, severe hypoxemia, hypercapnia, cardiac arrest, and fatal anoxic brain injury

Opioid overdose primarily impacts the central nervous and respiratory systems through profound mu-opioid receptor agonism in the brainstem, which blunts hypercapnic and hypoxic ventilatory drive

Clinical risk mitigation centers on identifying individuals with elevated vulnerability—such as those receiving high daily morphine milligram equivalents, taking concurrent central nervous system depressants, or experiencing reduced opioid tolerance—to avert acute respiratory failure and mortality

Clinical risk mitigation centers on identifying individuals with elevated vulnerability—such as those receiving high daily morphine milligram equivalents, taking concurrent central nervous system depressants, or experiencing reduced opioid tolerance—to avert acute respiratory failure and mortality